Abstract:Background: O6-methylguanine-DNA methyltransferase ( MGMT ) methylation status affects tumor chemo-resistance and the prognosis of glioblastoma (GBM) patients. We aimed to investigate the role of MGMT methylation in the regulation of GBM immunophenotype and discover an effective biomarker to improve prognosis prediction of GBM patients. Methods: A total of 769 GBM patients with clinical information from five independent cohorts were enrolled in the present study. Samples from the Cancer Genome Atlas (TCGA) dataset were used as the training set, whereas transcriptome data from the Chinese Glioma Genome Atlas (CGGA) RNA-seq, CGGA microarray, GSE16011, and the Repository for Molecular Brain Neoplasia (REMBRANDT) cohort were used for validation. A series of bioinformatics approaches were carried out to construct a prognostic signature based on immune-related genes, which were tightly related to the MGMT methylation status. In silico analyses were performed to investigate the influence of the signature on immunosuppression and remodeling of the tumor microenvironment. Then, the utility of this immune gene signature was analyzed by the development and evaluation of a nomogram. In vitro experiments were further used to verify the immunologic function of the genes in the signature. Results: We found that MGMT unmethylation was closely associated with immune-related biological processes in GBM. Sixty-five immune genes were more highly expressed in the MGMT unmethylated than the MGMT- methylated group. An immune gene-based risk model was further established to divide patients into high and low-risk groups, and the prognostic value of this signature was validated in several GBM cohorts. Functional analyses manifested a universal up-regulation of immune-related pathways in the high-risk group. Furthermore, the risk score was highly correlated to the immune cell infiltration, immunosuppression, inflammatory activities, as well as the expression levels of immune checkpoints. A nomogram was developed for clinical application. Knockdown of the five genes in the signature remodeled the immunosuppressive microenvironment by restraining M2 macrophage polarization and suppressing immunosuppressive cytokines production. Conclusions: MGMT methylation is strongly related to the immune responses in GBM. The immune gene-based signature we identified may have potential implications in predicting the prognosis of GBM patients and mechanisms underlying the role of MGMT methylation.

Insulin inhalation with absorption enhancer at meal‐times results in almost normal postprandial insulin profiles

Products of epidermal protein synthesis.

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis

Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction

Immu-15. Cd74/Mif Signaling Axis Disruption In Bone Marrow-Derived Myeloid Cells Delays Malignant Progression In A Preclinical Model Of Glioma

THE ROLE OF ICAM1 IN TUMOR ASSOCIATED MACROPHAGES IN GLIOBLASTOMA TUMORIGENESIS

Clinical Relevance and Interplay between miRNAs in Influencing Glioblastoma Multiforme Prognosis

Minilibraries constructed from cDNA generated by arbitrarily primed RT-PCR: an alternative to normalized libraries for the generation of ESTs from nanogram quantities of mRNA.

TAMI-31. MACROPHAGE M1 INVASION PREDICTS POOR PROGNOSIS OF GLIOMA AND REVEALS A STRATEGY FOR GLIOBLASTOMA THERAPY

Comprehensive Analysis of CD163 As a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.

Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma

Stimulation by Dendritic Cells That Binds B7-DC and Potentiates T Cell Naturally Occurring Human IgM Antibody

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma

A Quantitative Digital Analysis of Tissue Immune Components Reveals an Immunosuppressive and Anergic Immune Response with Relevant Prognostic Significance in Glioblastoma

Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

Defense of the Radical Perineal Prostatectomy

Glioma-derived M-CSF and IL-34 license M-MDSCs to suppress CD8+ T cells in a NOS-dependent manner

IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy

Thyroxine and Mammary Gland Growth in Rat.∗